sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Tideglusib

Tideglusib

CAS No.:
865854-05-3
Catalog Number:
AG00365G
Molecular Formula:
C19H14N2O2S
Molecular Weight:
334.3917
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
≥98%
1 week
United States
$91
- +
10mg
≥98%
1 week
United States
$123
- +
100mg
98+%
1 week
United States
$157
- +
Product Description
Catalog Number:
AG00365G
Chemical Name:
Tideglusib
CAS Number:
865854-05-3
Molecular Formula:
C19H14N2O2S
Molecular Weight:
334.3917
MDL Number:
MFCD18633296
IUPAC Name:
4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
InChI:
InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
InChI Key:
PMJIHLSCWIDGMD-UHFFFAOYSA-N
SMILES:
O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2
UNII:
Q747Y6TT42
Properties
Complexity:
492  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
334.078g/mol
Formal Charge:
0
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
334.393g/mol
Monoisotopic Mass:
334.078g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
65.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.3  
Literature
Title Journal
Promotion of natural tooth repair by small molecule GSK3 antagonists. Scientific reports 20170101
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. Journal of Alzheimer's disease : JAD 20130101
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. The Journal of biological chemistry 20120106
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. Journal of medicinal chemistry 20111222
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. Journal of medicinal chemistry 20110623
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. International journal of Alzheimer's disease 20110101
A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiology of disease 20090901
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. The Journal of neuroscience : the official journal of the Society for Neuroscience 20070523
Properties